To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide sildenafil therapy to eligible adult patients with
pulmonary arterial hypertension (PAH) and to the patients who completed the A1481142 study
for the treatment of PAH in Poland. Only safety and tolerability data will be collected in
these patients.
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.